Hochschulschrift
Sorafenib in patients with refractory or recurrent multiple myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Maße
-
30 cm
- Umfang
-
15 Blätter
- Sprache
-
Englisch
- Anmerkungen
-
Illustrationen
Rheinische Friedrich-Wilhelms-Universität Bonn, Dissertation, 2015
- Klassifikation
-
Medizin, Gesundheit
- Urheber
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.03.2025, 11:58 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Ähnliche Objekte (12)
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Patient Characteristics and Outcomes of Relapsed/ Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Patient Characteristics and Outcomes of Relapsed/ Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
Multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Patient Characteristics and Outcomes of Relapsed/ Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany